Zepbound (Tirzepatide) Constipation: Alternatives Without This Side Effect

First Ask What the Alternative Needs to Solve

An alternative may be considered because of persistent symptoms, overall treatment response, administration preferences or access. Those are different reasons. Record what happened on Zepbound, the dose history and which constipation treatments were tried before assuming another medicine will solve the problem.

The Zepbound label reports constipation in 17%, 14% and 11% of the 5 mg, 10 mg and 15 mg groups, versus 5% with placebo. These pooled rates do not show a steadily increasing dose relationship. Maintenance selection considers both response and tolerability; a reduction cannot be promised to preserve the same weight-loss response or resolve symptoms on a fixed schedule. [1]

Semaglutide Is an Alternative, Not a Constipation Guarantee

Wegovy's label lists constipation among its common adverse reactions. A historical rate from a separate study does not establish that switching from tirzepatide will improve an individual's symptoms. Wegovy and Ozempic should not be treated as interchangeable study regimens simply because both contain semaglutide. [2]

SURMOUNT-5 compared tirzepatide and semaglutide in an open-label, 72-week trial involving 751 adults with obesity without diabetes. It compared specified treatment regimens and average outcomes; it was not a trial of switching people with persistent constipation from one product to the other. Its abstract does not supply a constipation-specific switching success rate. [8]

A weekly schedule does not establish that every person should start another product the following week or that a universal no-washout protocol applies. The actual products, doses and clinical situation determine a transition plan.

Non-incretin Medicines Have Different Tradeoffs

Orlistat works differently from a GLP-1 medicine. Its label describes gastrointestinal effects including oily stools and fecal urgency. That profile is not proof that constipation can never occur or that it is the right alternative for everyone with bowel symptoms. [5]

Contrave and Qsymia both list constipation among common adverse reactions. Their different mechanisms do not establish that their constipation is necessarily milder or worse for an individual. Percentages from separate trials should not be used as a head-to-head tolerability ranking. [3, 4]

Orforglipron's Status Has Changed

The FDA approved Foundayo (orforglipron) on April 1, 2026 for long-term weight management in specified adults, alongside reduced-calorie eating and increased physical activity. Its initial label describes an oral GLP-1 receptor agonist and lists constipation among common adverse reactions. It should no longer be grouped with unapproved investigational agents in a May 2026 discussion. [6, 7]

Approval status does not prove that HealthRX.com sells the product, that an insurer covers it or that it is suitable for a particular patient. A new product's indication, actual availability and a person's response are separate questions. Oral administration also does not establish freedom from GLP-1-related gastrointestinal effects.

Constipation Treatment May Be a Separate Option

The joint AGA/ACG guideline supports several treatments for CIC, including PEG, fiber and prescription options with different evidence. That is useful context, but is not a validated tirzepatide rescue sequence. Magnesium oxide has very low-certainty evidence under a conditional recommendation; a universal 400-800 mg daily supplement regimen should not be presented as established. [9]

The existing symptoms of severe pain, prolonged inability to pass stool, distension or vomiting require evaluation rather than an automatic switch. Zepbound's postmarketing reports include obstruction, ileus and severe constipation, while frequency and causation remain difficult to establish from voluntary reports. [1]

Questions That Make an Alternatives Review Specific

Describe the bowel problem and treatment response. Ask which exact product and formulation is being considered, what evidence matches your situation, how the transition would be managed and what access or coverage needs checking. A manufacturer difference alone does not establish an insurer's prior-authorization decision; coverage depends on the actual plan.